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ABSTRACT 
THE EFFECTS OF ANTIBODIES IN DISEASE PROGRESSION OF MOG-
INDUCED EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS 
by 
Melissa Marie Riter 
 
The University of Wisconsin-Milwaukee, 2015  
Under the Supervision of Professor Jerri-Annette Lyons 
 
 
Abstract: Multiple sclerosis (MS) is an auto-inflammatory disease of the central 
nervous system (CNS), affecting over 400,000 people in the US. MS is primarily 
studied in the animal model experimental autoimmune encephalomyelitis (EAE). 
MS is a T cell mediated disease but there is mounting evidence for a role for B 
cells in MS. Previous studies have established that rMOG Induction depends on 
the presence of B cells, while induction using the MOG peptide covering amino 
acids 35-55 does not require B cells to cause disease. When plasma from the 
rMOG and MOG35-55 immunized WT mice was analyzed by ELISA there 
binding at MOG21-45, covering the encephalogenic epitope, and binding 
covering the MOG46-85 amino acids, which was not expected. This epitope was 
observed again in T cells when comparing the WT and B cell -/- mice. WT T cells 
only bound MOG35-55 but T cells from B cell-/- mice also bound MOG61-85. The 
same epitope observed in WT antibodies. This led to the conclusion that this was 
a cryptic epitope and seemed to produce an anti-inflammatory response. Mice 
coimmunized with both MOG35-55 and MOG61-85 similar results were observed 
as in rMOG immunization. Coimmunized mice had less severe disease than 
those immunized with just MOG35-55 giving further evidence that MOG61-85 
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produces a protective response. When rMOG immunized B cell -/- mice were 
given serum from rMOG primed WT mice clinical disease could be observed. 
This was also true for coimmunized mice. Meaning it was B cell products in the 
serum not the B cells themselves that was altering the immune response. When 
serum from MOG35-55 and MOG61-85 primed rabbit serum was used after heat 
inactivation, WT and B cell -/- mice showed more severe disease. B cell -/- mice 
given the immune serum also had an earlier onset of disease. This demonstrated 
that the most likely cause of the altered response was antibody. Cells from mice 
coimmunized injected with either immune rabbit serum or preimmune rabbit 
serum were cultured with MOG35-55 and MOG61-85, proliferation was 
measured. The mice in the preimmune group had greater proliferation to both 
peptides. This may be because the encephalogenic cells had already migrated to 
the CNS in the immune group. When T cells were cultured again with purified 
antibody, from rMOG primed mice, proliferation decreased in all the wells with 
antibody added, but when injected into coimmunized mice similar disease was 
observed as seen in the mice given immune serum. Over all these results 
indicate a role for antibody in the processing and presentation of MOG in EAE. 
This may be through the suppression of the presentation of MOG61-85 when 
antibody is bound to MOG when it is taken up by antigen presenting cells.  
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Chapter I: Introduction 
Multiple Sclerosis and Animal Model of Disease 
 Multiple sclerosis (MS) is a neurodegenerative, inflammatory disease of 
the central nervous system (CNS). MS affects 400,000 people in the United 
States and over 2.5 million worldwide (Smyth, 2011; Steinman, 2014). The 
etiology of MS is not fully understood, but studies have demonstrate that both 
genetic and environmental factors are important for disease development. Twin 
studies reveal a 25% concordance (Compston & Coles, 2008; Willer, et al., 2003) 
and there are studies linking 52 different genes to the development of MS, such 
as those for the major histocompatibility complex (MHC) (Gourraud, Harbo, 
Hauser, & Baranzini, 2012), and cytokines like interleukin-18 (Celik, et al., 2014). 
On the other hand, environmental factors associated with MS have ranged from 
diseases, such as Epstein Barr virus and measles (Sundqvist, et al., 2012), to 
cigarette smoking (Jafari & Hintzen, 2011) and vitamin D deficiency (Berlanga-
Taylor, Disanto, Ebers, & Ramagopalan, 2011). How these different factors lead 
to the development of MS is unknown.  
 MS patients can suffer from a variety of symptoms including pain, 
paralysis, balance problems, and bladder dysfunction (Fletcher & Mills, 2012). 
How the disease progresses will depend on the type of MS, and which symptoms 
occur will depend on where in the CNS the lesions occur (Noonan, et al., 2010). 
The two main types of MS are primary progressive MS (PPMS) and relapsing 
remitting MS (RRMS) (Noonan, et al., 2010; Smyth, 2011). 85% of MS patients 
present with RRMS, while only 15% present with PPMS (Noonan, et al., 2010). 
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PPMS exhibits a linear disease course. These patients may have plateaus in 
disease progression but once a symptom occurs, it becomes permanent. RRMS 
patients have intermittent disease and early in the disease course will fully 
recover from all symptoms during a remission. These relapses occur once every 
few years and last days to weeks (Steinman, 2014). Relapses are defined as a 
neurological change that lasts for at least 24 hours; not brought on by changes in 
body temperature (Steinman, 2014). Eventually these patients will no longer fully 
recover and symptoms become permanent. Patients may still have periods of 
remission, but disease progression may also change to a more linear disease 
course. At this point these patients would be considered secondary progressive 
MS patients (SPMS). About 50% of RRMS patients will progress to this stage 
(Smyth, 2011). There are treatments available for patients with RRMS, which 
slow disease progression, however, there is no effective treatment for PPMS or 
SPMS patients currently available (Cross & Waubant, 2011; Leary & Thompson, 
2005). 
 Clinical signs and symptoms of MS are caused by the development of 
plaques, or lesions, within the CNS. These plaques can be classified into four 
different types based on the cells and soluble proteins present.  Types I, II, and 
III are characterized by the predominance of macrophages and T cells 
contributing to inflammation near the blood brain barrier (Lucchinetti, et al., 
2000). Type I and II are separated by the presence of immunoglobulins and 
complement found primarily in type II plaques (Lucchinetti, et al., 2000; Serres, et 
al., 2009; Quintana, et al., 2008). Microglia contribute to inflammation in type III 
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plaques and are further separated by the diffuse inflammation observed with 
oligodendrocytes undergoing apoptosis (Lucchinetti, et al., 2000; Marik, Felts, 
Bauer, Lassmann, & Smith, 2007). Type IV also has diffuse inflammation and like 
type III, and DNA fragmentation is observed, but other signs of apoptosis are not 
seen (Lucchinetti, et al., 2000). Type III and IV do not show remyelination, unlike 
type I and II lesions where remyelination is observed (Lucchinetti, et al., 2000; 
Marik, Felts, Bauer, Lassmann, & Smith, 2007). The T cells found in different 
lesions of MS patients have different V-D-J junctional regions of the T cell 
receptor (TCR), which determine the specificity of the T cell (Friese & Fugger, 
2009; Huseby, Huseby, Shah, Rebecca, & Stadinski, 2012).This indicates that 
each lesion has the expansion of a different T cell clone producing a new 
population of specific T cells causing the damage within a single lesion.  
 The myelin sheath protects the axons of nerve cells and increases 
conductivity of nerve signals. In MS the myelin sheath is damaged, exposing the 
axon to damage and decreasing the conductivity of nerve signals. The sheath is 
a complex mixture of lipids (70%) and protein (30%). Three myelin proteins 
relevant to MS include: myelin basic protein (MBP), proteolipid protein (PLP), and 
myelin oligodendrocyte glycoprotein (MOG). MS patients produce an immune 
response to all three of these proteins (Greer, Cameron, McCombe, Good, & 
Pender, 1997; Meinl, et al., 1997; Hjelmström, Penzotti, Henne, & Lybrand, 
1998). MBP and PLP are the most abundant proteins in the CNS but they are not 
exposed to the environment (Greer, Cameron, McCombe, Good, & Pender, 
1997; Meinl, et al., 1997; Goverman J. M., 2011). Unlike MBP and PLP, MOG is 
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a transmembrane protein, which means that part of the protein is readily 
available for recognition by the immune system before any damage has been 
done to the myelin sheath, making it a prime candidate for the initiation of the 
autoimmunity characteristic of MS (Weber, Hemmer, & Cepok, 2011; Kursula, 
2008).   
 All three of these myelin proteins are used to induce experimental 
autoimmune encephalomyelitis (EAE), an animal model of MS. EAE is used to 
study the immune mechanisms of MS (van der Star, et al., 2012). The EAE 
model produces a disease similar to MS. The disease can be triggered by a 
single T cell clone specific to an epitope on a myelin protein, but the response 
can spread to other epitopes on the same protein or to epitopes on other myelin 
proteins (Zamvil, et al., 1985; Lehmann, Fursthuber, Miller, & Sercarz, 1992). 
The protein or peptide of protein is used to induce disease in susceptible animals 
(i.e. mice, marmosets, and rats) with the appropriate adjuvant. The protein or 
peptide used depends on the species and strain of animal being utilized (Lyons 
J.-A. , Ramsbottom, Mikesell, & Cross, 2008; van der Star, et al., 2012). Disease 
may also be induced using the passive transfer of immune cells or immunization 
with appropriate protein and serum from animals immunized with the appropriate 
protein in susceptible animals (Lyons, Ramsbottom, & Cross, 2002; van der Star, 
et al., 2012). This biggest criticism of the EAE model is that the disease in not 
spontaneous, but must be induced. Neither MS nor an MS-like disease occurs 
naturally in animals, but disease can develop spontaneously in mice genetically 
modified with transgenetic T cell receptors specific for MBP, but disease only 
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occurs under non-sterile conditions (Goverman, et al., 1993; Lafaille, Nagashima, 
Katsuki, & Tonegawa, 1994) 
The Immune Response in MS/EAE 
Effector CD4+ T cells  
 The immune response observed in MS was originally thought to be 
mediated by type 1 helper T (Th1) cells but this has been challenged with the 
discovery of Th17 cells. Th1 cells produce a T cell-mediated proinflammatory 
response through the production of proinflammatory cytokines like interferon 
(IFN)- ɣ. IFN-ɣ induces relapses in MS patients suggesting that an increase in 
Th1 cells may induce relapses in relapsing remitting MS (Steinman, 2014). Th1 
cells infiltrate the CNS and attract macrophages and natural killer cells to the 
CNS where they are activated, causing the release of more proinflammatory 
cytokines such as IFN-ɣ and tumor necrosis factor-α (TNF-α), which is toxic to 
oligodendrocytes (Hedegaard, et al., 2008). However, mice lacking IFN-ɣ or TNF-
α had worsened disease in EAE this information, led to the discovery of a role for 
Th17 cells in the pathology of disease (Steinman, 2014). Th17 cells also infiltrate 
the CNS in MS and have been observed in the cerebral spinal fluid of MS 
patients along with elevated levels of interleukin (IL)-17, the main cytokine 
produced by Th17 cells (Komiyama, et al., 2006; Matusevicius, et al., 1999). 
These cells are also implicated in the pathology of EAE (Kreymborg, et al., 2007; 
Komiyama, et al., 2006). IL-17 is known to disrupt the blood brain barrier 
(Compston & Coles, 2008). Furthermore Th17 cells recruit neutrophils to the 
CNS which, and like macrophages, can cause further damage (Fletcher, Lalor, 
Sweeney, Tubridy, & Mills, 2010). Both Th1 and Th17 cells are able to induce 
6 
 
 
 
EAE through the passive transfer of cells from immunized mice, but appear to do 
so through independent but complementary mechanisms (Fletcher, Lalor, 
Sweeney, Tubridy, & Mills, 2010). IFN-β ameliorates Th1 induced disease but will 
worsen Th17 induced disease (Fletcher, Lalor, Sweeney, Tubridy, & Mills, 2010). 
The ratio of Th1 and Th17 cells differ in the spinal cord of mice with EAE, but 
infiltration of the brain occurs when the Th17 cells outnumber the Th1 cells 
(Steinman, 2014). It’s thought that Th1 cells enter the brain first and these cells 
drive the MS-like disease and Th17 cells come later in the disease  (Steinman, 
2014). 
Cytotoxic T cells  
 Cytotoxic T cells (CD8+) like CD4+ helper T cells are found in the plaques 
of MS patients (Friese & Fugger, 2009; Fletcher, Lalor, Sweeney, Tubridy, & 
Mills, 2010). CD8+ T cells produce cytotoxic products, such as perforin and 
granzyme B; produce proinflammatory cytokines, such as TNF-α and IFN-ɣ; have 
cytolytic activity; and activate myelomonocytic cells (Friese & Fugger, 2009). 
CD8+ T cells cannot induce lysis in oligodendrocytes, but the myelomonocytic 
cells, with both monocytic and granulocytic characteristics can induce lysis in the 
oligodendrocytes, which produce the protective myelin sheath (Friese & Fugger, 
2009).  The amount of axonal damage in acute MS lesions has been correlated 
to the number of cytotoxic T cells infiltrating the lesions (Friese & Fugger, 2009; 
Huseby, Huseby, Shah, Rebecca, & Stadinski, 2012; Saxena, Martin-Blondel, 
Mars, & Liblau, 2011). There is also evidence that specific cytotoxic T cell clones 
migrate to the CNS in patients with MS, which then undergo further expansion 
(Friese & Fugger, 2009; Huseby, Huseby, Shah, Rebecca, & Stadinski, 2012). In 
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EAE cell transfer experiments, cytotoxic T cells have demonstrated the ability to 
induce disease (Friese & Fugger, 2009). It is unknown if cytotoxic T cells are part 
of the initiation of MS, but they appear to have a role in disease progression 
through their cytokine production in active MS lesions (Friese & Fugger, 2009). 
Regulatory T cells 
Several different subsets of CD4+ and CD8+ regulatory T cells have been 
identified (Correale & Villa, 2010). Both types of regulatory T cells suppress the 
immune response through cell-to-cell interaction and the production of anti-
inflammatory cytokines (Filaci, Fenoglio, & Indiver, 2011). CD8+ regulatory T 
cells can also regulate the immune response through cytotoxic mechanisms that 
are not fully understood (Tejera-Alhambra, et al., 2012; Filaci, Fenoglio, & 
Indiver, 2011). These cells are difficult to identify as they are present in smaller 
numbers than effector T cells; do not proliferate as much as effector T cells in 
response to stimulation; and there is no marker that identifies all regulatory T 
cells (Fallarino, et al., 2003; Filaci, Fenoglio, & Indiver, 2011). Both CD4+ and 
CD8+ regulatory T cells can be identified through the expression of the 
transcription factor forkhead box p3 (FOXP3), but not all CD8+ regulatory T cells 
are FOXP3 positive (Filaci, Fenoglio, & Indiver, 2011; Hu, Weiner, & Ritz, 2013). 
Only about half of the identified CD8+ regulatory T cell subsets are FOXP3 
positive (Filaci, Fenoglio, & Indiver, 2011) Two separate populations of CD4+ 
regulatory T cells produce the anti-inflammatory cytokines IL-10 (inducible 
regulatory T cells) and transforming growth factor (TGF)-β (Th3 cells) (Fletcher, 
Lalor, Sweeney, Tubridy, & Mills, 2010). TGF-β is a pleiotropic cytokine, the 
function of which is dependent on the context in which it is expressed. On its 
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own, TGF-β inhibits T cell proliferation, promotes regulatory T cell differentiation 
and may promote cell death (Travis & Sheppard, 2014; Bettelli, et al., 2006). 
However, in the presence of other cytokines like IL-2 cell death is inhibited and in 
the presence of IL-6, TGF-β promotes Th17 cell differentiation (Travis & 
Sheppard, 2014). CD4+ regulatory T cells suppression of effector T cells through 
cells-to-cell contact appears to be antigen specific, but this does not appear to be 
true for the CD8+ regulatory T cells (Sakaguchi, Wing, Onishi, Prieto-Martin, & 
Yamaguchi, 2009; Hu, Weiner, & Ritz, 2013). 
It has long been known that healthy individuals harbor myelin-reactive T 
cells. Why these cells remain quiescent in these individuals but are activated and 
lead to pathology in MS patients has long been a topic of investigation. Recent 
studies have found that CD4+ regulatory T cells from MS patients appeared to 
have less suppressive power than healthy controls when challenged in vitro and 
in vivo (Fletcher, Lalor, Sweeney, Tubridy, & Mills, 2010; Steinman, 2014; Korn, 
et al., 2007). Viglietta, Baecher-Allan, Weiner, and Hafle found that an ongoing 
immune response in healthy controls did not affect CD4+ regulatory T cells ability 
to suppress effector T cells in vitro, while MS patients CD4+ regulatory T cells 
were unable to suppress T cell activation in vitro (2004). This demonstrates that 
the ability of the regulatory T cells to suppress is altered in MS patients and that 
an active immune response in vivo does not affect the in vitro results.  
In EAE, the regulatory T cells were not observed to expand in the CNS, 
but the regulatory T cells that were able to enter the CNS produced IL-10 in 
response to stimulation with MOG35-55 (Korn, et al., 2007). Regulatory T cells 
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collected from mice immunized with MOG35-55 can suppress specific 
proliferation better than naïve cells, though both are equally able to suppress 
non-specific CD3 stimulated cells (Korn, et al., 2007). Effector T cells from the 
CNS were unable to be suppressed by regulatory T cells from the CNS, which 
appeared to be due to the combination of high IL-6 and TNF-α levels found in 
culture supernatants (Korn, et al., 2007). This may indicate that it is not just the 
activation of the immune system that is stopping the suppression of the effector T 
cells, but a problem with the CD4+ regulatory T cells ability to respond to the 
immune response.  
CD8+ regulatory T cells do not appear to be dysfunctional in MS, but are 
not present in normal numbers compared to healthy controls during relapse 
(Filaci, Fenoglio, & Indiver, 2011; Fletcher, Lalor, Sweeney, Tubridy, &Mills, 
2010; Correale & Villa, 2008). This is especially true in the CNS of MS patients 
(Correale & Villa, 2008). Correale and Villa found that the cloning frequency of 
CD8+ regulatory T cells was not altered in MS patients (2010). CD8+ regulatory 
T cells that are also Foxp3+ are able to reduce dendritic cells ability to present 
myelin antigens to effector T cells through the downregulation of costimulatory 
molecules in vitro (Correale & Villa, 2010). Cunnusamy et al. found that 
suppression of CD4+ effector T cells by CD8+ regulatory T cells was decreased 
in transwell culture compared to co-cultures with cells from MS patients (2014). 
This demonstrated that some of the suppressive ability of CD8+ regulatory T 
cells is through cell to cell contact but they also have some suppressive ability 
through cytokine production. CD8+ regulatory T cells in MS are reduced in 
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numbers but do not lose their ability to suppress, indicating that it may be that 
CD8+ regulatory T cells are not able to enter the CNS effectively or their 
numbers are not high enough to suppress the effector T cell response (Correale 
& Villa, 2008).  
Type 2 helper T cells 
 Th2 cells, like regulatory T cells, are anti-inflammatory cells in MS. Th2 
cells are normally part of the humoral immune response and are implicated in 
allergies. Th2 cells produce IL-10, IL-4, IL13 and IL-5, which suppress the 
differentiation of Th1 cells and direct the differentiation of B cells and isotype 
switching in antibodies (Oreja-Guevara, Ramos-Cejudo, Stark Aroeira, 
Chamorro, & Diez-Tejedor, 2012; Celik, et al., 2014; Levings, et al., 2001).Th2 
cell differentiation is blocked by TGF-β (Travis & Sheppard, 2014). In in vitro 
experiments, neurons incubated with Th2 cells were protected from damage 
caused by a Th1 response (Yong, Giuliani, Xue, Bar-Or, & Metz, 2007). This is 
hypothesized to be through the production of cytokines such as IL-10 (Yong, 
Giuliani, Xue, Bar-Or, & Metz, 2007). 
Th2 cells do not have a role in the progression of MS but Th2 cytokines 
are up regulated during a relapse along with Th1 cytokines in RRMS patients (de 
Andrés, et al., 2004). The cytokines produced by Th2 cells inhibit the 
differentiation of Th1 cells. There has been research to determine how to shift the 
T cell response toward Th2 cells and away from Th1 and Th17 response, 
through the modulation of the immune response (Smolders, et al., 2009; Oreja-
Guevara, Ramos-Cejudo, Stark Aroeira, Chamorro, & Diez-Tejedor, 2012). This 
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is how many of the treatments for MS currently work though this is not enough to 
stop disease progression.  
Research on treatments for MS that push the immune response toward to 
a Th2 response are under development. It has been observed that vitamin D can 
promote Th2 cell differentiation and increase Th2 cytokine levels in MS 
(Smolders, et al., 2009; Sloka, Silva, Wang, & Yong, 2011). Vitamin D deficiency 
has also been implicated as one of the environmental factors associated with the 
development of MS, as many MS patients are vitamin D deficient (Berlanga-
Taylor, Disanto, Edbers, & Ramagopalan, 2011; Correale, Ysrraelit, & Gaitán, 
2011). Vitamin D in its bioactive form, 1,25-dihydroxyvitamin D3, produces Th2 
cells in culture of human cells through the induction of the STAT6 transcription 
factor, which is important for Th2 cell differentiation (Sloka, Silva, Wang, & Yong, 
2011).  
Another treatment is peptide vaccine. Myelin protein peptides are injected 
in high doses to induce a Th2 response (Pearson, van Ewijk, & McDevitt, 1997). 
In the EAE model, it has been found that injections of high doses of peptide with 
low T cell binding affinity can induce the apoptosis of Th1 cells and cause new T 
helper cells to differentiate into Th2 cells (Pearson, van Ewijk, & McDevitt, 1997; 
Katsara, et al., 2009). More recently, an analog of MBP, glatiramer acetate (GA), 
has been used to treat MS. GA induces Th2 cytokines and reduces Th1 
cytokines in MS patients (Oreja-Guevara, Ramos-Cejudo, Stark Aroeira, 
Chamorro, & Diez-Tejedor, 2012; Chen, et al., 2001). These patients also had a 
reduced number of relapses and a reduction in the number of lesions seen on 
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MRI scans (Oreja-Guevara, Ramos-Cejudo, Stark Aroeira, Chamorro, & Diez-
Tejedor, 2012). The exact mechanism of GA is still under investigation. 
B cells in MS/EAE 
 The role of B cells in the pathogenesis of MS has been controversial. 
Scientists agree that B cells play a role in the pathogenesis but what that role is, 
is still under debate. This is due to inconsistent results observed between studies 
because of differences between animal models and methods used (Lyons J.-A. , 
Ramsbottom, Mikesell, & Cross, 2008; Liu, Muili, Agashe, & Lyons, 2012; Lyons, 
San, Happ, & Cross, 1999; Wilson, 2012; Abdul-Majid, et al., 2002; Urich, 
Gutcher, Prinz, & Becher, 2006; Cross, Trotter, & Lyons, 2001; Dittel, Urbania, & 
Janeway, 2000; Hjelmström, Penzotti, Henne, & Lybrand, 1998; Wolf, Dittel, 
Hardardottir, & Janeway, 1996). There are several possible roles for B cells in 
MS including: antigen presentation, production of proinflammatory cytokines, 
secretion of antibodies, and regulation of the immune response.  
B cells as APCs 
 Activated B cells are considered professional antigen presenting cells 
(APC). B cells are potent APCs to T cells specific to the same antigen as the B 
cell. For a B cell to present antigen, it must first bind antigen via the B cell 
receptor (BCR). The antigen is broken down through antigen processing, 
followed by presentation on the major histocompatibility complex (MHC) class II 
molecule. The MHC/antigen complex interacting with T cell receptor (TCR) must 
come together with the interaction of the B7 costimulatory molecule on the APC 
with CD28 expression by the T cell. This leads to T cell activation and cytokine 
production. Which cytokines are produced is dependent on the APC and the 
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environment in which T cell activation is occurring, leading to the generation of 
either a pro- or anti-inflammatory response (Nakae, Iwakura, Suto, & Galli, 2007).  
 Other antigen presenting cells like dendritic cells can present antigen 
taken up non-specifically (i.e. pinocytosis, phagocytosis), while B cells need to 
bind antigen specifically by the BCR to efficiently present antigen (Chesnut & 
Grey, 1981). B cells can perform pinocytosis and bind antibody via the Fcɣ-
receptor but these are not presented efficiently to T cells (Chesnut & Grey, 
1981). This means that B cells only efficiently present antigen that they bind via 
the BCR and T cells activated by B cells can only be presented epitopes in the 
MHC molecule from the antigen bound by cross-linking on the BCR before 
processing (Grey, Colon, & Chesnut, 1982).  Once the BCR bound antigen is 
taken in to the cell the antigen is transported to the early endosome compartment 
and then quickly transported to the late endosome compartment where MHC 
class II molecules are assembled (Cheng, Steele, Gu, Song, & Pierce, 1999).  
There is evidence that interactions with B cells are needed for T cells to 
become activated and enter the CNS (Ireland & Monson, 2011; Harp, Lovett-
Racke, Racke, Frohman, & Monson, 2008). Furthermore, Duddy et al. (2007) 
found that the maturity of the B cell may affect the cytokines produced in 
response to activation, creating either a pro- or anti-inflammatory response. They 
observed that naïve and memory B cells produced different cytokines on 
activation and that these cytokines differed depending on if B cell activation was 
antigen specific or by bystander mechanisms (Duddy, et al., 2007). This 
observation, along with the success of the B cell depletion therapy for some MS 
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patients (Harp, Lovett-Racke, Racke, Frohman, & Monson, 2008; Morris & 
Yiannikas, 2012; Naismuth, et al., 2010), has led to the belief that T cell-B cell 
interactions are an important part of disease progression in MS. Harp et al. 
(2010) found that B cells from some RRMS patients could induce T cell 
proliferation and IFN-ɣ production when stimulated with MBP and/or MOG, this 
was not true for B cells from Healthy controls. They also demonstrated both 
memory B cells and naïve B cells could induce T cells proliferation in response to 
MOG, but MBP could only induce proliferation when presented by memory B 
cells (Harp, et al., 2010). The effectiveness of B cells as APCs to T cells may be 
a reason that B cell deletion therapy has been an effective treatment for some 
MS patients (Ireland & Monson, 2011). 
 There are several things that can effect which antigens are presented to T 
cells including the amino acid sequence of the antigen, the presence of antibody 
bound to the antigen at the time of internalization, and regulating proteins in the 
MHC assembly compartment (Alfonso, et al., 2003). In other antigen presenting 
cells DM, a regulatory protein for MHC assembly which favors epitopes that 
stably bind to MHC, is found as free heterodimers, while in B cells DM is closely 
associated with DO, another MHC associated heterodimer protein found only in 
B cells and some subsets of dendritic cells (Alfonso, et al., 2003; Kropshofer, 
Hämmerling, & Vogt, 1999). This association means that antigen loading, 
mediated by DM-DO, can only occur in a more acidic environment compared to 
that of DM alone (Roucard, et al., 2001). DO is upregulated after BCR mediated 
antigen up take and alters the presentation of some epitopes by either 
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suppressing or promoting them though the acidic environment of the 
endoplasmic reticulum, where MHC is assembled (Alfonso, et al., 2003; Roucard, 
et al., 2001).   
Another factor that can alter epitope presentation is the presence of 
antibody bound to the antigen at the time of internalization (Simitsek, Campbell, 
Lanzavecchia, Fairweather, & Watts, 1995). Like the binding of DO, the binding 
of soluble antibody to antigen can suppress or promote selection of epitopes 
(Simitsek, Campbell, Lanzavecchia, Fairweather, & Watts, 1995).  The antibody 
to antigen ratio determines if the T cells response to the antigen is promoted or 
suppressed (Manca, Fenoglio, Pira, Kunkl, & Celada, 1991). This has been 
observed in all antigen presenting cells (Manca, Fenoglio, Pira, Kunkl, & Celada, 
1991; Watts & Lanzavecchi, 1993).   
Cytokine production by B cells 
B cells can produce several different proinflammatory cytokines including 
IL-6, IFN-ɣ, Lymphotoxin (LT)-α, and TNF-α (Barr, et al., 2012; Ireland & Monson, 
2011; Christensen, et al., 2012; Serafini, Rosicarelli, Magliozzi, Stigliano, & 
Aloisi, 2004). Barr et al. demonstrated that B cell produce 86% of IL-6 in 
secondary lymphoid tissue in EAE and another study found that neutralization of 
IL-6 reduced disease in EAE (Erta, Quintana, & Hidalgo, 2012). IL-6 is a 
proinflammatory cytokine important for the differentiation of Th17 cells and 
plasma cells (Erta, Quintana, & Hidalgo, 2012). IFN-ɣ is also produced by B cells 
which pushes the immune response toward a Th1 response (Ireland & Monson, 
2011). 
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 Another cytokine produced by activated B cells is LT-α, which is important 
for the formation of memory B cells, and along with TNF-α is associated with the 
formation of ectopic follicles in the CNS (Ireland & Monson, 2011; Christensen, et 
al., 2012; Serafini, Rosicarelli, Magliozzi, Stigliano, & Aloisi, 2004). Ectopic 
follicles have been observed post mortem in MS patients and in EAE, and are 
made up of follicular dendritic cells and proliferating B cells (Serafini, Rosicarelli, 
Magliozzi, Stigliano, & Aloisi, 2004). The formation of these ectopic follicles is 
associated with an increase in production of pro-inflammatory cytokines.  
The role of antibody in MS/EAE 
B cells that differentiate into plasma cells produce antibodies, which can 
affect disease through multiple mechanisms including, activation of the 
complement cascade, Fc receptor binding, and epitope selection. Antibody 
bound to a cell’s surface can initiate the complement cascade, which can lead to 
phagocytosis of the cells by macrophages or the formation of the membrane 
attack complex causing damage to the cell membrane (Piddlesden, Lassmann, 
Zimprich, Morgan, & Linington, 1993). Phagocytosis can also occur through 
binding of the Fc region of the antibody when antigen is bound (Dharmasaroja, 
2003; Abdul-Majid, et al., 2002). Furthermore, antibody-dependent cell-mediated 
cytotoxicity is mediated by the binding of the Fc region by macrophages or 
natural killer cells, inducing the release of inflammatory molecules, which leads to 
the lysis of the target cell (Dharmasaroja, 2003; Piddlesden, Lassmann, 
Zimprich, Morgan, & Linington, 1993). All of these actions have been observed in 
MS lesions (Breij, et al., 2006; Dharmasaroja, 2003). 
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 Antibody specific to myelin proteins has been observed postmortem in 
lesions of MS patients, the cerebral spinal fluid (CSF), and serum, but these 
antibodies have also been observed in the serum of healthy controls, indicating 
that the presence of myelin antibodies does not indicate disease when it is only 
present in the periphery (Lucchinetti, et al., 2000; Villar, et al., 2005; von 
Büdingen, et al., 2004). The bands found in the CSF and not the serum is a sign 
of inflammation and antibody production in the CNS (Weber, Hemmer, & Cepok, 
2011). These antibodies are termed oligoclonal bands and are found in about 
90% of MS patients (Compston & Coles, 2008). The presence of these bands 
increases the likelihood that the patient will develop clinically definite MS, as 
opposed to a clinically isolated episode (Miller, Chard, & Ciccarelli, 2012). Those 
patients that do not develop oligoclonal bands are thought to have a more mild 
disease course (Huttner, et al., 2009; Rojas, Patrucco, Tizio, & Cristiano, 2012). 
The presence of more oligoclonal bands indicates a more severe disease course 
(Weber, Hemmer, & Cepok, 2011; Miller, Chard, & Ciccarelli, 2012; Cross, 
Trotter, & Lyons, 2001).The presence of oligoclonal bands is used as a 
diagnostic tool to help determine if the patient has MS, but oligoclonal bands are 
not specific to MS (Miller, Chard, & Ciccarelli, 2012). Oligoclonal bands can also 
be found in patients with late stage Lyme disease and neurosyphilis (Pachner & 
Steere, 1985; Vartdal, Vandvik, Michaelsen , Loe, & Norrby, 1982). 
Epitope spreading is a process by which responses to new epitopes are 
developed during an immune response. These new epitopes are not overlapping 
with the original epitope and may or may not be on the same protein as the 
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original epitope (Vanderlugt, et al., 1998). This can occur in both the T cell and 
antibody repertoire. Epitope spreading could follow tissue damage, making new 
epitopes available for binding, or though the processing of antigen allowing 
different epitopes to be presented. Epitope spreading of antibodies to several 
myelin proteins has been correlated with the rate of relapse in three different 
models of EAE and is thought to proceed in an ordered progression (Lehmann, 
Fursthuber, Miller, & Sercarz, 1992; Robinson, et al., 2003; Yin, et al., 2001; Yu, 
Johnson, & Tuohy, 1996).  In EAE and at least some MS patients, the original 
immunodominate epitope losses its capacity to stimulate the immune response, 
but new epitopes take the place of the original epitope progressing the 
autoimmune response (Tuohy, Yu, Yin, Kawczak, & Kinkel, 1999). This could be 
due to the damage in the CNS allowing APCs like B cells to bind new epitopes 
and present them to T cells, leading to the activation of a new set of autoreactive 
T cells (Bischof, et al., 2004). The T cells then in turn would activate new 
autoreactive B cells (Bischof, et al., 2004).  
Antibodies specific to conformational epitopes are known to cause 
demyelination in animal models using the extracellular MOG sequence, while 
antibodies to linear epitopes do not, which is hypothesized to be because they 
cannot bind native MOG (Breithaupt, et al., 2008; von Büdingen, et al., 2004; 
Brehm, Piddlesden, Gardinier, & Linington, 1999). In other models where MOG 
peptide is used to induce EAE, antibodies to linear epitopes are found to be 
pathogenic (von Büdingen, et al., 2004). Antibodies binding conformational 
epitopes have also been found in MS patients, while antibodies to linear epitopes 
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have been found in both MS patients and healthy controls (Breithaupt, et al., 
2008). Conformational epitopes are thought to come first, activating B cells. The 
B cells activate T cells using linear epitopes, which then activate B cells reactive 
to these linear epitopes.  
Regulatory B cells 
 There is a subset of B cells that have properties similar to those seen in 
regulatory T cells. In EAE, regulatory B cells produce IL-10 in response to toll-like 
receptor (TLR) 2 and 4 signaling (Ray, Mann, Basu, & Dittel, 2011). TLRs are 
proteins found on the membrane of cells and in cells that activate the immune 
response though the binding of conserved structural motifs found in bacteria and 
viruses. In EAE, regulatory B cells are required for recovery mediated by 
regulatory T cells (Marín, et al., 2014). Regulatory B cells also regulate the 
immune response through cell-to-cell interactions with T cell by binding of the B7 
and CD80/CD86 proteins (Ray, Mann, Basu, & Dittel, 2011; Mauri, 2010). Unlike 
regulatory T cells, regulatory B cells do not appear to be defective in MS patients 
and when stimulated produced significantly more IL-10 than healthy controls 
(Ray, Mann, Basu, & Dittel, 2011). Furthermore, there is also evidence that direct 
regulatory B cell interaction with T cells though CD28 and B7 is required for 
recovery in EAE (Ray, Mann, Basu, & Dittel, 2011; Mizoguchi, Mizoguchi, Preffer, 
& Bhan, 2000). This interaction may cause the activation of regulatory T cells, 
since the regulatory T cell response is delayed in EAE when B cells are removed 
(Ray, Mann, Basu, & Dittel, 2011; Mann, Ray, Basu, Karp, & Dittel, 2012; 
Matsushita, Horikawa, Iwata, & Tedder, 2010). Additionally, B cell depletion 
before induction of EAE with MOG35-55 increases disease severity, while 
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depletion after disease onset decreases disease severity (Yanaba, et al., 2008; 
Matsushita, Yanaba, Bouaziz, Fujimoto, & Tedder, 2008). This indicates that 
regulatory B cells are more important early on in EAE. 
Previous Studies 
Our Previous data demonstrated that B cell-deficient (B cell-/-) mice are 
not susceptible to EAE induction using the whole rMOG protein, but WT mice are 
susceptible rMOG induction. This indicates that B cells are required for EAE 
induction using rMOG. But when B cell-/- mice were injected with the MOG35-55, 
the encephalogenic epitope of the MOG protein, the mice developed EAE like the 
WT mice (Lyons et al., 1999). We also found that disease could be reconstituted 
 
Figure 1: Serum 
antibody ELISA of 
rMOG or MOG35-85 
peptide immunized 
mice. WT animals were 
immunized with rMOG or 
MOG35-55 peptide and 
serum was collected. A 
serum antibody ELISA 
was performed to 
determine the specific 
antibody responses, 
observed with each 
antigen. The animals 
immunized with rMOG 
or MOG35-55 
demonstrated a 
response against 
MOG21-40, but 
antibodies were also 
observed in the rMOG 
immunized mice 
against amino acids 
46-85. 
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in the B cell-/- through the transfer of B cells or serum from rMOG primed WT 
mice (Lyons, Ramsbottom and Cross, 2002). Plasma ELISA of the rMOG 
induced WT mice reveled antibodies to linear epitopes between aa46-85 that 
were not observed in the MOG35-55 induction (Figure 1) (Lyons et al., 
unpublished data; Liu et a., 2012).  
Next T cell epitopes were studied. The expected encephalitogenic aa35-
55 epitope was observed in the WT and B cell-/- mice primed with rMOG. In 
addition, a novel epitope at aa61-85 was observed in B cell-/- but not WT mice 
(Figure 2) (Lyons et al., unpublished data; Liu et al., 2012).  When B cell-/- mice 
were co-immunized with MOG35-55 and MOG61-85 epitopes, disease severity 
was decreased when compared with a MOG35-55 induction. Similar results were 
observed in WT mice, which led to the conclusion that MOG61-85 is a cryptic  
 
 
epitope, which is protective against the development of EAE (Figure 3) (Lyons et 
al., unpublished data; Liu et al., 2012). This amelioration was observed whether 
the peptide immunizations occurred at the same or different locations (Figure 3) 
Figure 2: B cell-/- mice, but not WT B6 
mice, respond to MOG61-85, when 
immunized with rMOG. WT and B cell-/- were 
immunized with rMOG in CFA. T cells were 
isolated via negative selection from draining 
lymph nodes 10 days post immunization. 
Proliferation to a panel of overlapping 20-
25mer peptides spanning the rMOG protein 
was evaluated. Analysis exposed an 
additional response to MOG61-85 by T 
cells isolated from B cell  -/- mice that was 
not observed in WT mice. 
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(Lyons et al., unpublished data). This was corroborated by EAE induction with 
MOG35-85 peptide, containing both the protective and encephalogenic epitopes. 
Immunization of B cell-/- or WT mice with this longer peptide resulted in reduced 
disease severity and incidence compared to MOG35-55 induction (Figure 4) 
(Lyons et al., 1999; Lyons et al., unpublished data). This indicates that B cell 
products have a role in disease initiation and perhaps in regulating the selection 
of the MOG61-85 epitope.  
 
 
 
A. 
●  MOG35-55 alone 
○  MOG35-55 + MOG61-85 
■ MOG61-85 alone 
 
B. 
C. D. 
Figure 3: Coimmuization of B6 mice with MOG35-55 and MOG61-85 at different 
sited (left side) or at same site (right side) ameliorates EAE. WT (A, B) or B cell-/- (C, 
D) C57BL/6 mice were immunized with the encephalitogenic MOG35-55 alone (closed 
circles) or with MOG61-85 (open circles), and the clinical course of EAE was followed. 
EAE clinical course was significantly less severe in animals co-immunized with 
both peptides compared to animals receiving MOG35-55 alone, regardless of strain 
(WT vs. B cell-/-). Immunization with MOG61-85 alone (closed squares) failed to 
induce clinical EAE.  
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Hypothesis and Aims 
 Previous studies in the EAE model have demonstrated that B cells are 
required when rMOG is used for induction but not with the MOG35-55 induction. 
Later studies demonstrated B-and T- cell responses unique for specific epitopes 
in WT and B cell -/- mice immunized with MOG35-55 and MOG61-85. In 
particular, a cryptic epitope was identified in the 61-85 amino acid sequence 
which reduced severity of disease in WT and B cell -/- mice.  
 This work was to determine the effects of serum in disease progression of 
EAE induction with both MOG35-55 and MOG61-85 epitopes on the disease 
progression and cellular response to primed serum or purified antibody from 
primed serum. I hypothesized that antibody specific for linear epitopes of rMOG 
Figure 4: Immunization with MOG35-85 peptide results in a decreased disease 
severity in WT and B cell -/- animals as compared to the animals immunized with 
MOG35-55. Animals were immunized with the appropriate peptide and observed for a 
period of 29 days post immunization for EAE induction and progression. This graph shows 
the complied results of all three experiments. Reduced disease severity in WT and B  
cell-/- mice demonstrated the protective nature of the longer peptide. 
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in primed serum alter the immune response toward a proinflammatory response. 
I addressed this with the following aims.  
Specific Aims: 
1. Determine the effect of antigen primed serum on disease severity and 
proliferation in response to antigen. Working Hypothesis: was that the 
response to the cryptic MOG61-85 epitope is blocked by the presence of 
serum primed with the MOG35-55 and MOG61-85.  
2. Determine the effect of purified antibody on disease severity and 
proliferation in response to antigen. Working Hypothesis: was that the 
response to the cryptic epitope MOG61-85 will be blocked by the 
presence of purified antibody primed with rMOG.  
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Chapter II: Materials and Methods 
Mice 
Specific pathogen free, female, WT C57bl/B6 mice and B cell-/- on a B6 
background that were 6-8 weeks old were used for these experiments. All mice 
used were bred in-house from breeding pairs purchased from Jackson 
Laboratories (Bar Harbor, ME). Animals were housed in an Association for 
Assessment and Accreditation of Laboratory Animal Care (AAALAC) accredited 
facility on the University of Wisconsin Milwaukee (UWM) campus according to 
university and National Institutes of Health (NIH) guidelines. All protocols used 
were approved by the Institutional Animal Care and Use Committee.  
Antigens 
 The MOG35-55 (MEVGWYRSPFSRVVHLYRNGK), and MOG61-85 
(QAPEYRGRTELLKDAIGEGKVTLRI) peptides were obtained from GenScript 
(Piscataway, NJ). These peptides were commercially synthesized and then 
purified by High Performance Liquid Chromatography (HPLC). A 120 amino acid 
sequence that makes up the extra cellular domain of human MOG, rMOG, was 
isolated from culture supernatants of High-5 insect cells infected with a 
recombinant baculovirus expressing the rMOG protein (Devaux, Enderlin, 
Wallner, & Smilek, 1997). 
Immunizations 
 Mice were immunized with 100 µg of rMOG or 50 µg of MOG35-55 and 
MOG61-85 each emulsified in incomplete Freund’s adjuvant (IFA, MP 
Biochemicals, Solon, OH) with 300 µg Mycobacterium tuberculosis strain H37RA 
(TB, Difco Laboratories, Detroit, MI). Emulsions were prepared using Omni 
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Homogenizer mechanical mixer and were injected subcutaneously at 4 sites, 
near each limb. 300 ng of pertussis toxin (PT) (List Biological labs, Inc., 
Campbel, CA) in Phosphate Buffered saline (PBS-200mg/L, KCl-200mg/ml, 
KH2PO4-8000 mg/L, NaOH-1150 mg/ml Na2HPO4) was also injected 
intraperitoneally at the time of immunization and 72 hours post immunization. 
Mice were injected with 100 µL of heat inactivated serum, from rabbits 
immunized with MOG35-55 or MOG61-85 in a 1:100 dilution in normal mouse 
serum, or serum from rabbits before immunization, preimmune serum, at the time 
of immunization and three days following immunization. The serum was heat 
inactivated by incubating serum at 55C overnight, this was done for all rabbit 
serum used. This was done to inactivate complement present in the serum 
samples, which could harm the mice if the complement was still active at the time 
of injection. Purified antibody injections followed the same injection schedule as 
the serum. The antibody was injected as a 1:100 dilution in PBS.  
EAE grading 
 Mice were graded for the signs of clinical disease starting at 10 days post 
immunization. The mice are graded on a scale from 0-5. Mice receiving a score 
of 0 are free of clinical signs of disease; a score of 1 reflects a loss of muscle 
tone in the tail (tail fails to “helicopter” when picked up); a score of 2 indicates 
mice are unable to right themselves when placed on their backs; a score of 3 
signifies paralysis or weakness in one hind limb; a score of 4 represents the 
paralysis of both hind limbs; a score of 5 indicates the mice are dead or 
moribund. Mice observed for clinical disease were graded for up to 30 days.  
27 
 
 
 
Cell culture 
 For in vitro experiments, mice were euthanized 26-30 days post 
immunization (dpi). Mice were anesthetized using ketamine (100 mg/ml), and 
xylazine (300 mg/ml) mixture (1 ml ketamine + 0.15 ml xylazine + 4.6 ml water) 
injected intramuscularly or inhalation of isoflourane. If serum was to be collected 
then the mice were pinned down on a tray and cardiac puncture was performed 
to collect serum and then cervical dislocation was performed. If no serum was 
collected then after anesthetization cervical dislocation was performed before 
mice were pinned to tray. The mice were then squirted with reagent grade 
ethanol and an incision was made between the back legs of mouse then the skin 
was separated from the peritoneal cavity. The incision was then extended up the 
front of the mouse and each leg. The skin was then pinned open and squirted 
with ethanol to remove any loose fur. The lymph nodes (LN) were removed using 
tweezers and suspended in Hanks Balanced Salt Solution (HBSS). The 
peritoneal cavity was then opened using scissors and the spleen (SPL) removed 
using tweezers and suspended in HBSS. The LN and SPL were then 
homogenized in sterile glass homogenizers and centrifuged to separate the cells 
from the debris and fat. The SPL also had the red blood cells removed using 
Lymphocyte Separation Media (LSM;MP Biomedical, Aurora, HO) or red blood 
cell lysing buffer (Sigma, St Louis, MO). The cells were treated with tyrpan blue 
(90 μl of 0.4% tyrpan blue solution + 10 μl of the cells) and counted using a 
hemocytometer to determine viability and concentration of cells. Cell 
concentration was determined using the following formula: 
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(No. of cells counted) (Dilution factor) (104)/ No. of squares counted = cells/mL 
Cells were cultured in complete RPMI 1640 [penicillin (100 U/mL)/streptomycin 
(100 µg/mL), L-glutamate (2 mM), sodium pyruvate (0.1 mM), 2-mecarptoethanol 
(50 mM)] with 10% Fetal bovine serum (FBS) added. The cells were also 
cultured with the appropriate antigen (MOG35-55, MOG61-85) at a concentration 
of 20µg/mL, or Con A at 10µg/mL at a cell density of 2.5x106 cells/mL. A fourth 
group was set up with no antigen present as a control. Cells were cultured up to 
four days at 37˚ C with 10% CO2.  
Serum collection 
Mice were sedated using either isoflourane or a cocktail of molecular grade 
water, ketamine, and zylazine. The mice were then pinned at each limb on a 
dissection tray. A cardiac puncture was performed to remove to blood to tubes 
containing 10µL of EDTA. The blood was kept on ice until all samples were 
collected. The blood was centrifugated for 3 min 30 seconds at 2500rpm. The 
serum was pipetted off into new tubes, pooled, aloquoted to 100µL per tube and 
frozen at -80C until used.  
Purification of IgG Antibody 
IgG antibody was purified from mouse serum primed with rMOG. The purification 
was done using magnetic bead purification (generous gift of Dr. Susan 
Frackman, Promega, Madison, WI). Briefly, the beads were added to the tubes 
and placed in magnet allowing the storage solution to be removed. The beads 
were washed using the bind/wash buffer (25mM sodium acetate, pH 6). The 
beads were mixed and then replaced in the magnet and the bind/wash buffer 
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removed. Then 50µL of sample was added to 50µL of bind/wash buffer. This was 
added to the beads and mixed continually for 30 minutes. The tube was then 
placed back in the magnet and the supernatant removed and saved, this is the 
serum in bind/wash buffer minus the IgG. The beads are washed three times in 
the bind/wash buffer. 50µL of Elution buffer (100mM glycine-HCl, pH 2.7) was 
added to the beads and mixed continually for 5 minutes. The beads were placed 
in the magnet and the elutant was removed to a new tube and 10µL of the 
neutralization buffer (2M Tris buffer, pH7.5). The elution was repeated. The titer 
and purity of the elutant was determined using a serum antibody ELISA.  
Antigen Presenting Cell Preparation 
APCs were obtained from the spleen (SPL) of naïve WT mice. The SPL were 
collected and prepped for culture as stated above with no antigen. Cells were 
spun (500g 10min) and resuspended to a concentration of 8.1x106 cells/mL. 
Then 100µL of mitomycin C (MP Biomedical, Aurora, OH) was added to the cells. 
The cells were incubated in a water bath at 37C for 20 minutes, protected from 
light. Cells were washed 3 times in HBSS with 5% FBS. Cells were cultured in 
complete RPMI with 10% FBS at the concentration of 8.1x106 cells/mL in a 96 
well plate, 100µL per well and were incubated at 37C with 10% CO2 for 1 hour. 
The cultures were mixed and the media removed and discarded. 100µL of 
complete RPMI with 10% FBS was added to the wells. The APCs will adhere to 
the wells so that the non-APCs were removed with the media after the wells were 
mixed.  
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T cell purification 
T cells were purified using magnetic beads (STEMCELL, Vancouver, BC ). 
Lymph nodes (LN) from immunized mice were prepped as stated above. The 
cells were spun (500g, 10min) and resuspended at a concentration of 
1x108cells/mL in 1mL HBSS with 2% FBS. 50µL of normal mouse serum was 
added to the cells. Then 50µL of EasySepTM mouse CD4+ T cell isolation cocktail 
was added and mixed well. This was incubated at room temperature for 10 
minutes. While cells incubated EasySepTM streptavidin RapidSpheresTM  for 30 
seconds. Then 75µL of the RapidSpheresTM was added to the cells and mixed 
well. This was incubated for 2.5 minutes at room temperature. The total volume 
was brought up to 2mL by adding HBSS with 2% FBS and mixed well. The cells 
were then placed in the magnet for 2.5 minutes. The tube was then picked up in 
the magnet and the supernatant containing the purified T cells was poured into a 
new tube. The cells were recounted using the same method as before. The T cell 
purity was checked using flow cytometry using CD4, CD8 and CD19 as markers. 
The percent purity was determined using Flow Jo software. The purified T cells 
were then plated with the naïve APCs at a concentration of 2.5x106cells/mL with 
either no antigen; Con A (10µg/mL); MOG35-55 (10µg/mL); or MOG61-85 
(10µg/mL). All of these were plated for 48 and 72 hour readings with the CCK-8 
protocol along with a set of the cells with a 1:100 dilution of purified IgG antibody 
read at 72 hours. 
Proliferation 
Cells were obtained from LN and SPL were suspend in RPMI+10% FBS in tubes 
to bring the cell starting concentration to 2.5x106cells/mL.  The antigens were 
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added to the cells at the appropriate concentrations. The cells were then plated 
in duplicate in a 96 well plate 100μL per well. Wells with just RPMI+10% FBS 
were used as a control. CCK-8 stain (Mayflower,St Louis,MO)was added (10μL) 
per well and incubated at 37˚ C with 10% CO2 for four hours. The optical density 
was measured using a Synergy™ HT Multi-Mode Microplate Reader (450nm; 
Biotek, Winooski, VT).The cells were cultured for 48, 72, or 96 hours. The 
standard used to determine cell concentrations at the time the optical density 
was read was read at 24 hours. The standard cells were cultured with no antigen 
and diluted 5 times using a 1:2 dilution starting at 2.5x106cells/mL as the top of 
the standard.  
Serum Antibody ELISA 
The specificity of the serum collected was determined using a peptide antibody 
ELISA. Peptides spanning the length of the rMOG protein were used to verify the 
antibody specificity of IgG and IgM was consistent between collections. 96 well 
plates (Corning Costar 9018) were coated using rMOG as a positive control and 
just the bicarbonate coating buffer (sodium carbonate, sodium bicarbonate, 
sodium azide, in deionized water pH9.6) as a negative control. Each of the 
peptides was diluted to 10µg/mL in the coating buffer. These were incubated 
over night at 4C. The wells were washed four times in a solution of PBS and 
0.05% Tween 20. Blocking buffer (1.5g of BSA in 50mL of PBS) was added. This 
was incubated for 2 hours. The plate was washed four times. The serum was 
then added to the wells in two dilutions, 1:100 and 1:400, for each peptide and 
immunoglobulin. The serum was diluted in dilution buffer (0.05% PBT, 0.5%BSA 
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in PBS). This was incubated for one hour before washing four times. The 
secondary antibody specific to either murine IgG or murine IgM was diluted to 
1:40,000 or 1:20,000, respectively, and added to the wells. This incubated for 
one hour. The plate was then washed once more and TMB substrate solution 
from BD bioscience. The plate was incubated for 15 minutes before the stop 
solution (2.5N sulfuric acid) was added to the wells before reading on the 
Synergy™ HT Multi-Mode Microplate Reader (450nm and 562nm; Biotek, 
Winooski, VT).  
Statistics 
 All statistics were run using the computer program prism graphpad. All p-
values were set to 0.05 for significance. Differences in disease severity were 
determined by a two-tailed T-test of the area under the curve for all mice in each 
group. Day of onset was day first clinical signs of disease were observed no 
number was given if mouse never displayed signs of disease. Proliferation 
experiments were tested for significance using two-way ANOVA.  
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Chapter III: Results 
WT and B cell-/- mice were coimmunized with MOG35-55 and MOG61-85. 
The mice were given two PT injections, at the time of immunization and day two 
post immunization. Preimmune or immune serum was injected on day of 
immunization and for 3 days following. An ELISA was run on the rabbit serum to 
verify the specificity of the antibodies in the serum. The mice were followed for 
clinical signs of disease. Both WT and B cell-/- mice injected with the immune 
 
serum showed more severe signs of disease compared to mice given the 
preimmune serum in the B cell -/- groups but not enough of the preimmune B 
Figure 6: WT and B cell -/- mice were coimmunized with MOG35-55 and MOG61-85, 
with preimmune rabbit serum or serum isolated from rabbits immunized with the 2 
MOG peptides. The error bars represent standard error of the mean. WT and B cell-/- 
mice injected with immune serum had more severe disease compared to those receiving 
pre-immune serum. The WT mice were euthanized early (17dpi) due to tail biting 
behavior observed. The B cell-/- mice were followed for 34 dpi. These data demonstrate 
that the immune serum had an effect on disease severity in the B cell-/- mice. 
 
Figure 5: Mean disease severity over the course of 
the disease course seen above in WT and B cell-/- 
mice. There was no significant difference observed 
between the preimmune and the immune groups for 
either the WT (p=0.114) or the B cell-/- mice (p=0.054). 
This may have been due to small group sizes in the B 
cell-/- mice. In the mice that displayed signs of 
disease in B cell-/- recipients of immune serum, the 
disease severity was much higher than those that 
received pre-immune serum. 
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cell-/- mice became sick to run a t-test (figure 5). This may be due to the 
introduction of primed antibody to the immune system allowing the adaptive 
immune response to be activated earlier in the disease 
 
 
 
course. The day of onset was not significant in the WT mice (p-value=0.99). This 
may have been because the WT mice produce their own antibody response. The 
B cell -/- mice in the immune group had severe disease, while the preimmune 
group had only minimal disease severity and incidence. The disease mean 
disease severity was higher in the immune groups compared to the preimmune 
groups in both the WT (p-value=0.114) and the B cell -/- (p-value=0.054) (figure 
6). Significance was not reached in either group but both tended toward 
significance and the group size was small. Both groups of WT mice were 
sacrificed 17 dpi due to tail biting observed in the immune serum group. Serum 
antibody ELISAs were run on serum taken from the WT mice to determine if the 
rabbit antibodies could still be found. I was able to observe the presence of rabbit 
IgG in the serum of the WT mice in the immune group. B cell -/- mice were not 
Figure 7: To investigate the mechanism of protection in recipients of immune 
serum, the experiment was repeated with B cell -/- and IL-10 -/- mice. Mice were 
followed for 26 days. The error bars represent the standard error of the mean. The B 
cell-/- mice receiving immune serum demonstrated more severe disease 
compared to mice receiving pre-immune serum. However there was little 
difference observed between the same to groups of IL10-/- groups. 
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sacrificed until 34 dpi serum, spleens, and lymph nodes were collected. The 
Lymph nodes from the preimmune B cell -/- group were observed to be larger 
than expected from B cell -/- mice.  
IL-10 deficient (IL-10-/-) mice and B cell -/- mice were coimmunized with 
MOG35-55 and MOG61-85 as previously described. These mice were also split 
into immune and preimmune serum groups. These mice were followed for 26 dpi 
for clinical signs of disease (Figure 7). The day of disease onset was significantly 
different in the B cell -/- mice in the preimmune and immune groups (p-
value=0.0079) (Figure 4). No significant difference in the day of onset was 
observed in the IL-10-/- mice (p-value=0.7919). The mean disease severity was 
significantly higher in the B cell -/- immune mice compared to the preimmune 
group (p-value=0.0159) (Figure 8). The IL-10-/- mice mean severity did not reach 
significance comparing the immune and preimmune groups (p-value=0.0952).  
Once again the Lymph nodes from the B cell -/- mice in the preimmune group 
were observed to be larger than expected. 
                   
 
 
Figure 8: The Mean disease severity was determined using the area under the curve 
on the disease course graphs. No significant difference was observed between the IL-10-/- 
groups (p=0.0952), but there was a significant difference between the B cell -/- immune and 
preimmune groups (p=0.0159). This was also true for the day of onset of disease (p=0.0079) 
for the B cell -/- mice. These data demonstrate that injection of immune serum at the 
time of immunization increases disease severity in B-/- mice but not in the IL-10-/- 
mice, suggesting that IL10 may be important in the observed clinical effect. 
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The Lymph nodes and spleens were homogenized and cultured for CCK-8 
testing at 48, 72, and 96 hours, with no antigen, Con A, MOG35-55, MOG61-85, 
or both MOG35-55 and MOG61-85 (Figure 9). The absorbance was measured to 
determine the proliferation in response to the stimuli. Proliferation was observed 
to all three MOG cultures but the proliferation was higher in the preimmune 
group. The difference in proliferation did not reach significance possibly due to 
the small number of mice in each group. This along with the observation of the 
larger than normal lymph nodes in the preimmune group led to the conclusion 
that MOG61-85 presentation leads to the trapping of T cells in the lymph nodes 
stopping their migration to the CNS. 
 
 
  
 
 
To investigate the response of T cells to MOG35-55 and 61-85 with naïve 
APCs, SPLs were collected from naïve WT mice and treated with mitomycin C to 
stop the cells from proliferating. To ensure the culture only contained APCs the 
cells were incubated for an hour at culture conditions, then the cultures were 
Figure 9: The immune response to MOG35-55 and MOG61-85 in mice receiving pre-
immune or immune serum at the time of immunization was investigated using the CCK-
8 proliferation assay. Lymph node (LN) cells were isolated from B cell-/- mice receiving pre-
immune or immune serum and cultured with the indicated peptides in vitro for 48, 72, or 96 
hours. Con A was used as a control for cell viability. Increased proliferation was observed 
by cells from mice receiving pre-immune serum 72 hours for the MOG35-55 and MOG61-
85 groups, and for the MOG35-55+61-85 the same between the immune and preimmune 
but the preimmune group was higher at 72 and 96 hour but this did not reach 
significance. This suggests that the immune serum may be directing the development of 
the T cell response, thus affecting disease severity in the EAE model. 
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mixed and the media removed. This allowed the APCs to adhere to the culture 
plate so that only the T and B cells were removed with the media. The APCs 
were then incubated over night at culture conditions in RPMIc with 10% FBS. 
The next day LNs were collected from B cell -/- mice coimmunized given either 
immune or preimmune serum. The LNs were prepped for culture and then T cells 
were purified from the cell suspension. The T cells were checked for purity using 
flow cytometry staining for CD8, CD4, and CD19. Purity was determined to be 
 
 
 
greater than 97% (figure 10). Purified T cells were cultured with the mitomycin C 
treated APCs. These were cultured for 48 or 72 hours. At 24 hours some of the 
cells were treated with purified IgG from rMOG primed mice which were read at 
72 hours. The purified antibody was tested with an ELISA to determine purity. 
The ELISA showed that only IgG was in the elutent and that this was enriched for 
IgG. There was little IgM seen even in the serum after the IgG was purified from 
Figure 10: Flow cytometry of purified T cell suspension. The cells were stained 
with CD4, CD8, and CD19. The cells were gated for Lymphocytes and then for CD4 
and CD8. CD19 was used as a negative control and no CD19 was used staining was 
observed. The CD4+ T cell population was found to be over 97% pure in both the 
cells from the immune and preimmune groups. 
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it, though some of the IgG remained behind. These cells were read with the 
CCK-8 dye. I found a higher response in the preimmune group to MOG61-85 at 
both the 48 and 72 hour time point (Figure11). There was very little if any 
response to the MOG35-55 this may been due to the number of freeze thaws the 
peptide underwent. This experiment demonstrated that there is a T cell specific 
 
response to MOG61-85 in the preimmune group that is lost with the addition of 
the immune serum. The proliferation seen also shows that this response is not 
due to the carryover of antigen in APCs from the in vivo response as the APCs 
used were naïve and did not contribute to the proliferation observed due to the 
treatment of mitomycin C. Some of the wells had purified IgG from rMOG primed 
WT mice added to the wells at 24 hours; these were read at 72 hours. The IgG 
was tested for purity using ELISA and this was also used to determine the titer of 
the antibody (figure 12). The titer of the purified IgG was 
Figure 11: Proliferation response to MOG35-55 and MOG61-85 in purified T cells 
from the LN in B cell -/- mice coimmunized given either immune or preimmune 
serum was investigated using the CCK-8 assay. T cells were purified from the LN 
of B cell -/- coimmunized receiving either immune or preimmune serum. The T cells 
were cultured with naïve APCs treated with mitomycin C and the MOG peptide 
indicated in the graph for 48 to 72 hours. Con A was used as a positive control for cell 
viability.  There was a greater response to MOG61-85 in the preimmune group. 
This was expected as B cell -/- mice produce a T cell response to MOG61-85 in 
vivo. The immune group had little response to MOG61-85 and it occurred earlier 
than in the preimmune group. This demonstrated that The T cells are 
proliferating in response to MOG61-85 in the preimmune group and that this 
response is not due to antigen carried over by APCs.  
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determined to be about 1:500 while the IgM left in the sample was 1:1000 but the 
IgM did not dilute out as expected. The purified IgG was free of IgM but the 
serum sample still had IgG though much less than the purified IgG of the elutant. 
This may mean that the purification beads bind some IgG subclasses better than 
others making the purified IgG enriched with those subclasses. It is also 
important to note that the antibody and serum was diluted 1:2 in the purification 
process. There was also a reduction in the absorbance measured in both IgG 
and IgM was reduced overall. This is most likely due to the purification process 
and possibly the freezing and thawing of the samples. The addition of the 
Figure 12: Serum antibody ELISAs of serum and purified antibody from rMOG 
immunized WT mice. The top 2 graphs are the ELISAs run shortly after collection. The 
bottom graphs are the show the titers of the serum sample and the eluted purified IgG 
antibody. There was an overall decrease in detectable antibody in both isotypes most likely 
because of the dilution that occurred during purification. The IgG was further reduced due to 
the incomplete purification. This means that the purification resulted in antibody 
enriched for IgG subclasses due to better binding by the magnetic beads. 
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antibody was expected to increase the response to the MOG35-55 while 
 
 
 
decreasing the response to MOG61-85. This was not observed, instead there 
was an overall decrease in the response observed in the wells treated with IgG 
(Figure 12).  This may have been because the IgG was polyclonal and not 
specific for MOG peptides. The polyclonal IgG may be producing a regulatory 
response, which may be similar to that of Intravenous immunoglobulin (IVIG). 
IVIG produces a regulatory response and is used to treat many diseases 
including autoimmune and inflammatory diseases. This means that to produce 
the expected proinflammatory response the antibody may need to be purified 
down to those antibodies specific to MOG61-85 and MOG35-55.  
Figure 13: Proliferation response of purified T cells from the LN of B cell -/- mice 
coimmunized, and incubated with naïve APCs after 72 hours of culture. The groups 
marked +IgG had purified polyclonal IgG added to make a 1:100 dilution at 24 hours. The 
addition of the IgG produced an overall decrease in the proliferation across all 
treatments. This may have been due to the IgG being polyclonal causing an IVIG 
like effect on the cells.  
 
41 
 
 
 
 To determine if the same response would be observed in vivo mice were 
injected with IgG purified from the serum of WT mice immunized with rMOG. IgG 
from naïve mice was used as a negative control using the same purification 
method as the primed IgG. Rabbit serum was used in earlier experiments was 
used as a positive control. The antibody and rabbit serum was diluted to a 1:100 
solution in PBS, or normal mouse serum respectively and injected in the 
coimmunized B cell -/- mice at the time of immunization and the following 3 days. 
The mice were followed for clinical signs of disease (figure 14). The day of onset 
 
 
 
 
was not significant comparing the immune IgG and naïve IgG. The disease 
severity trended toward significance between the 2 groups (p-value=0.2729). The 
mice in the immune serum showed no signs of clinical disease this may be due 
to a loss of potency of the serum because of the length of time since the serum 
had been defrosted. Both the immune IgG and naïve IgG groups started to show 
Figure 14: Coimmunized B cell -/- injected with immune IgG, naïve IgG, or immune 
serum and followed for clinical signs of disease. The left graph shows the clinical 
course of disease for all 3 groups. The immune serum appears to have lost potency over 
time. The mean disease severity was determined by the area under the curve. The mice in 
both IgG groups showed clinical signs of disease but the mice given naïve IgG did not have 
as severe disease and began to recover earlier (p-value=0.2143). The recovery of the 
naïve IgG group may have been due to an IVIG effect. This demonstrates that 
antibody is important in initiation and disease progression. 
42 
 
 
 
signs of disease about the same time but naïve IgG group began to recover 
faster than the immune IgG group. This may mean that antibody is important in 
the initiation disease but specific antibody is important for progression of disease. 
It is also possible that the naïve IgG produced an IVIG effect leading to the 
recovery of the mice that did show clinical signs of disease.  
 Together this data demonstrates that in EAE the protective effects of 
MOG61-85 produced in B cell -/- mice coimmunized with MOG35-55 and 
MOG61-85 is blocked by the addition of B cell products in serum, specifically 
antibody. Evidence here suggests that IgG, possibly a specific subclass of IgG, is 
altering the T cell response in B cell -/- mice most likely by affecting the 
processing and presentation of MOG protein causing the MOG61-85 epitope to 
be suppressed in WT mice. I also found evidence of how MOG61-85 may be 
stopping the pro-inflammatory response. LN in the B cell-/- mice given the 
preimmune serum were larger than that of the mice injected with immune serum, 
which indicates that MOG61-85 may act by sequestering the T cell in the LN. 
This supports other work in this lab suggesting that MOG61-85 induces the 
production of TGF-β, which can alter immune cells ability to migrate (Wright, et 
al., 2003).  
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Chapter IV: Discussion and Conclusion 
Discussion 
This lab previously found that when EAE is induced with rMOG, B-/- mice do not 
show clinical signs of disease, while disease severity increased to be similar to 
that of the WT mice when immunized with MOG35-55 alone. This demonstrated 
that B cells are required for rMOG induction of EAE in this model. Another 
observation in rMOG induction was that B-/- mice produce T cells specific to 
MOG61-85, which are not found in WT mice immunized with rMOG.  WT mice 
were found to produce antibodies to the MOG61-85 epitope. This lab has also 
shown that mice coimmunized with the encephalogenic epitope, MOG35-55, and 
the protective MOG61-85 epitope have reduced clinical disease in WT and B-/- 
mice. When I immunized mice with both peptides and injected primed rabbit 
serum, disease severity increased. This further indicated that the change in 
clinical disease is caused by products produced by the B cells present in the 
serum. The most likely candidate for this product is antibody. This also 
demonstrated that it is most likely a response to MOG61-85 that is causing the 
change in EAE severity because the severity of disease increased when serum 
was added that was primed to MOG35-55 and MOG61-85 but not serum from 
naïve rabbits indicating that antibody to other peptides was not involved in this 
response.  
It is accepted that antibodies to conformational epitopes of myelin proteins 
contribute to demyelination in MS and in some models of EAE (Lucchinetti, et al., 
2000; Villar, et al., 2005; von Büdingen, et al., 2004; Piddlesden, Lassmann, 
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Zimprich, Morgan, & Linington, 1993; Dharmasaroja, 2003). Our analysis 
demonstrated antibodies specific for linear epitopes in WT mice immunized with 
rMOG also play a role. The presence of these antibodies was consistent between 
serum samples over several different experiments, and were consistently 
demonstrated to be predominantly of the IgG subclass. This was also true of the 
slight difference observed in the binding of the IgG and IgM in the peptides 
covering the MOG35-55 epitope. The IgM bound MOG21-40 and the IgG bound 
MOG21-45. This could just be an alteration in the binding between isotypes but 
this may be important for how the antibodies affect disease in EAE.  In fact the 
only time these results significantly differed was when the serum sample was 
from mice only 11dpi. In this case the antibodies spanning peptides covering 
amino acids 46-85 were IgM antibodies instead of the IgG previously seen. This 
indicates that isotype switching occurs early on in disease progression around 
when the first signs of clinical disease can be observed. This important to note 
since this occurs early on in the progression the class switching may be 
important for how antibody is affecting the presentation of MOG61-85. This has 
been observed in experiments investigating the processing and presentation of 
tetanus toxoid and hen egg lysozyme are used as antigen (Simitsek, Campbell, 
Lanzavecchia, Fairweather, & Watts, 1995; Amigorena, et al., 1998). This will 
require a careful study of the time-course of the development of the antibody 
response with rMOG immunization. Another possible study would be to 
determine if the MOG35-55 and MOG61-85 antibodies work together or 
independently in disease.  
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When clinical disease was observed in WT mice, mice in the immune 
group had more severe disease than that of the preimmune group. While this did 
not reach significance it demonstrates a trend that may have continued to reach 
significance, if the biting behavior had not occurred or if repeated as it represents 
a trend that was also observed in the B-/- mice. In the B-/- mice the disease 
severity did reach significance when repeated. The B-/- mice also show a 
significant difference in the day of onset of clinical disease not observed in the 
WT mice. This may be due to the lack of B cells and therefore antibody in the B-/- 
mice. The antibody response in WT mice develops quickly so that the addition of 
immune antibody does not affect disease onset just the severity of disease. 
While in B cell-/- mice the addition of antibody that would not normally be present 
cause clinical signs to develop earlier and increases severity of disease. The 
rabbit antibody was observed to still be present in the serum of WT mice 17 dpi. 
Further tests should be run to determine if this is also true in the B-/- mice.  
 I also looked at the proliferation in cell culture to determine the effects of 
serum on the response of immune cells to MOG35-55 and MOG61-85. While 
these results were not significant, a trend can be observed in the responses in 
the immune and preimmune groups, which may become significant when 
repeated. There was more proliferation in the preimmune group compared to the 
immune group in both the MOG35-55 and MOG61-85 conditions at 72 hours but 
by 96 hours the numbers had dropped back down to similar to the levels seen in 
the immune group. This could indicate that the activated cells are sequestered in 
the LN in the preimmune group, while in the immune group these cells have 
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migrated to the CNS by the time the LN were collected. Another indication of this 
was the observation that the LNs in the preimmune group were larger than those 
in the immune group. This could be determined by comparing the lymphocytes in 
the CNS and the periphery. This would make sense, since previously this lab 
found that IL-10 is not involved in the protection produced by the MOG61-85 
epitope and the next cytokine candidate currently being investigated is TGF-β. 
TGF-β is known to be able to alter cell migration in several organs including bone 
marrow, gut, and endothelium (Wright, et al., 2003; Zhang & Bevan, 2013; 
Godefroy, Guironnet, Jacquet, Schmitt, & Staquet, 2001).  
Although there was no significant difference observed in the clinical 
disease course in IL-10-/- mice when injected with immune or preimmune serum 
at immunization, this could be due to the small number of mice in these groups 
and may reach significance if repeated. One difference to note in the IL-10-/- 
mice was that the preimmune group had more severe disease than that of the 
immune group. This indicates that IL-10-/- is not a factor in the effect produced 
by the MOG61-85, which is consistent with all the other data collected by this lab 
that indicates that IL-10 is not important in the MOG61-85 response. Another test 
that could help determine if IL-10 is important would be an IL-10 ELISA on cell 
culture supernatants and previously when ELISAs were run on cell culture 
supernatants only very low amounts if any IL-10 were present. 
 When the proliferation of T cells was measured from cultures with naïve 
APCs, I found the preimmune group had a stronger response to MOG61-85 at 
both the 48 and 72 hour time points than the immune group. There was only a 
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small response to MOG61-85 in the immune group. The small response to 
MOG61-85 observed in the immune group could be explained by results 
previously demonstrated by this lab that when the peptides are injected in a 
single emulsion there is a response produced to both peptides in both WT and B-
/- mice (Liu, Muili, Agashe, & Lyons, 2012). There was no response to MOG35-
55 in either the preimmune or immune group. This may have been due to the 
high number of freeze thaws that the peptide had gone through. This could have 
caused the peptide to denature losing the reactivity in culture.  
At 72 hours culture there were also wells with purified IgG added to some 
of the wells these were compared to the wells without IgG added. The wells with 
the IgG added had a decreased response to both peptides and the positive 
control Con A. This could be explained by the IgG producing a regulatory 
response similar to that of intravenous immunoglobulin (IVIG), is a polyclonal 
pool of all immunoglobulin subclasses. IVIG is used to treat autoimmune and 
inflammatory diseases and is known to induce regulatory T cell expansion and 
enhance their suppressive capabilities (Ballow, 2011; Maddur, et al., 2010).  This 
may explain the reduction in proliferation to all stimuli observed in the cultures 
with IgG added. This may also mean that antibodies may need to be further 
purified to exclude all but those specific to MOG35-55 and MOG61-85 to see the 
expected results in cell culture.  
To determine if this effect would be observed in vivo mice were 
coimmunized and injected with purified IgG from rMOG primed serum or naïve 
IgG from WT mice. The mice given the immune IgG showed more severe 
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disease than the naïve IgG group. Furthermore, the naïve IgG group recovered 
faster than the immune IgG group. This may have been due to the same IVIG 
effect observed in the cell cultures. The disease course of the mice also indicated 
that antibody is important for disease initiation but also for disease progression in 
this model of EAE. The antibody used in this experiment was of the IgG isotype 
but based on the results of the ELISA analysis is most likely has more of some 
subclasses of IgG than others due to the incomplete purification of the serum 
sample. According to the Promega protocol the magnetic beads bind most 
strongly to the IgG1 and IgG2A subclasses but also bind IgG2B and IgG3. The 
subclasses present in both the sample and the eluted antibody should be 
determined to give a better indication of the mechanism of action of the IgG, 
since different subclasses are known to promote or inhibit epitope selection 
(Vidarsson, Dekkers, & Rispens, 2014). The role of IgM in the initiation of 
disease should also be ruled out in future studies.  
Conclusion 
Together these studies indicate that IgG is altering the processing and 
presentation of MOG protein in B6 mice. Alfonso et al. demonstrated that the 
addition of specific immunoglobulin to cultures inhibited the presentation of 
epitopes known to be presented in the absence of immunoglobulin (2003). I 
hypothesize that this occurs when APCs take in antigen bound by antibodies 
specific to MOG61-85 epitope through pinocytosis or Fc receptor binding. The 
suppression of epitopes in other models has not been able to be blocked by any 
available knock-out (Heyman, 2014).  This gives credence to pinocytosis as the 
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entry method of the antigen-antibody complex over the Fc receptor. Though it 
does not rule out that more than one entry rout is used. Once the antigen-
antibody complex it is taken in to the APC the complex moves to the endocytic 
compartment. Here the complex is exposed to a low pH environment. It is 
possible that the bound antibody affects the breakdown of MOG protein into 
epitopes in the endosome. Another possibility is that the antibody affects the 
peptides, produced in the endosome, ability to bind to the MHC. I think the 
alteration of peptide production is more likely since antibody is not stable in acidic 
environments. The altered MOG61-85 peptide may be too short, too long or not 
have side chains that allow it to create a stable binding with the MHC molecule. 
So that when the epitope tries to bind to the MHC the regulator protein MHC-DM 
removes MOG61-85 from the MHC because the binding is not stable enough. 
Meaning that MOG61-85 is not presented to T cell only MOG35-55 is presented 
leading to a proinflammatory response.   
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Figure 15: Effect of antibody on epitope selection. The antibody-antigen complex 
enter the cell and are broken down in the acidic environment of the endosome. The 
presence of the antibody changes how the antigen breaks down in the endosome so that 
the MOG61-85 epitope (teal)  cannot be presented. The peptide may be shortened, 
too long, or no long have the kinetic stability to bind the MHC (green). In any of 
these cases the peptide is not presented.  
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